<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542695</url>
  </required_header>
  <id_info>
    <org_study_id>18112</org_study_id>
    <secondary_id>NCI-2018-00890</secondary_id>
    <secondary_id>18112</secondary_id>
    <nct_id>NCT03542695</nct_id>
  </id_info>
  <brief_title>64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy</brief_title>
  <official_title>Use of 64Cu-DOTA-Alendronate PET Imaging for Localization and Characterization of Breast Calcifications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I pilot trial studies how well 64Cu-DOTA-alendronate positron emission
      tomography (PET) imaging work in localizing and characterizing breast calcifications (small
      calcium deposits) in participants before undergoing mastectomy. Diagnostic procedures, such
      64Cu-DOTA-alendronate PET, may detect calcification and help doctors predict cancer
      associated calcification within breast tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the uptake (maximum standardized uptake value [SUVmax]) of
      64Cu-DOTA-alendronate in female patients with biopsy-proven malignant breast calcifications.

      SECONDARY OBJECTIVES:

      I. To compare uptake of 64Cu-DOTA-alendronate on PET -computed tomography (CT) with histology
      after mastectomy.

      OUTLINE: This is a dose-escalation study of 64Cu-DOTA-alendronate.

      Participants receive 64Cu-DOTA-alendronate intravenously (IV) and undergo PET/CT imaging 60
      minutes after injection. Participants with sufficient levels of residual radioactivity may
      undergo repeat imaging on day 1 as determined by the study team.

      After completion of study , participants are followed up for 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum standardized uptake value (SUVmax) of 64Cu-DOTA-alendronate in evaluating tumor size and calcifications</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Tumor size sensitivity and the ability to detect calcifications will be compared to the extent of calcifications seen on mammogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uptake of 64Cu-DOTA-alendronate on positron emission tomography (PET) scan compared to histology after mastectomy</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Calcification</condition>
  <arm_group>
    <arm_group_label>Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 64Cu-DOTA-alendronate IV and undergo PET/CT imaging 60 minutes after injection. Participants with sufficient levels of residual radioactivity may undergo repeat imaging on day 1 as determined by the study team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper Cu-64-DOTA-alendronate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)</arm_group_label>
    <other_name>64Cu-DOTA-alendronate; [64Cu]-DOTA-alendronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)</arm_group_label>
    <other_name>PHARMACOKINETIC</other_name>
    <other_name>PK Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (64Cu-DOTA-alendronate, PET/CT scan)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of calcifications on mammogram

          -  Biopsy confirmed malignancy associated calcifications in at least one breast

          -  Biopsy confirmed benign calcifications in at least one breast (same or contralateral
             breast)

          -  Planned total mastectomy for treatment

          -  Ability to provide informed consent

          -  Negative serum pregnancy test

          -  No evidence of impaired hepatic or kidney function

        Exclusion Criteria:

          -  Participants who do not have residual calcifications present on mammogram following
             biopsy

          -  Concurrent malignancy other than non-melanoma skin cancer

          -  Patients with known metastatic disease

          -  Patients who have received prior treatment for the current breast cancer

          -  Patients currently using oral bisphosphonate therapy

          -  Patients with injection of other radioactive material within 90 days

          -  Inability to provide informed consent

          -  Pregnant or lactating patients

          -  Patients with impaired kidney function (creatinine &gt;= 1.3 mg/dL or &lt; 0.6 mg/dL)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Veronica C. Jones, MD</last_name>
      <phone>626-471-7100</phone>
      <email>vjones@coh.org</email>
    </contact>
    <investigator>
      <last_name>Veronica C. Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

